Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / UCB
Company

UCB

Tracked across 2 events · 13 articles · First seen Jul 13, 2026 · Last active Aug 19, 2026

Sentiment
30
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
2 40
Business
Antengene receives $60M from UCB
Impact: UCB obtained worldwide exclusive license to develop and commercialize ATG-201, expanding its autoimmune disease pipeline. The upfront payment and potential milestones represent a strategic investment.
Jul 13, 2026 · 7 articles
2 20
Business
Antengene presents R&D at Evercore Summit
Antengene Corporation Limited, a commercial-stage global biotech company listed on the China — Hong Kong Stock Exchange (SEHK: 6996.HK), presented key research and development highlights at the Evercore 2nd China Biotech Summit. The company disclosed…
Impact: UCB is a partner that has licensed an Antengene TCE candidate, benefiting from potential pipeline expansion.
Jul 20, 2026 · 6 articles
Key Actions (1)
50 Antengene out-licensed drug candidates UCBAntengene presents R&D at...
ERGEN INTELLIGENCE
Track UCB live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.